Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by unplugged1on Dec 01, 2023 11:49am
115 Views
Post# 35763553

RE:youtube has some bits about labs

RE:youtube has some bits about labssorry, not picking on Avant, it's a solid company cash flow + and I own that too but, that last q was really good for LABS much improved. I see them for sure hitting + adjusted ehbitda and cash flow + in 2024, like they're projecting. everything seems to be aligning just right.

VIVO buy was very shrewd for 8 million.  Practically embarrassingly so.  Abcann paid 133million for that , and we got it for 8. This might just be the very best buy in the industry.  OGI looks great too.

whomever that was that did that 40-page report a while back hats off mate,  It was amazing!



<< Previous
Bullboard Posts
Next >>